Diffuse Large B-cell Lymphoma: Clinical Trials

53 trials for Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

53 completed. 53 Phase 2, 12 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 253Completed 53
Phase 112Completed 12
Phase 32Completed 2

Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 53 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma
Mosunetuzumab Intravenous (IV), Mosunetuzumab Subcutaneous (SC), Polatuzumab Vedotin - Diffuse Large B-cell Lymphoma
Phase 1 / Phase 2CompletedHoffmann-La Roche1882019-05-232025-08-21
Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
Pembrolizumab - Non-Hodgkin Lymphoma, Lymphoma
Phase 2CompletedNational Cancer Institute (NCI)122018-02-152023-11-28
BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)
Zanubrutinib, Rituximab - Marginal Zone Lymphoma, Follicular Lymphoma
Phase 2CompletedBeiGene412018-01-042024-10-26
Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma
Zanubrutinib - Diffuse Large B-cell Lymphoma
Phase 2CompletedBeiGene412017-06-302024-10-26
Maintenance Therapy of Chidamide in Patients With HBV Positive Diffuse Large B-cell Lymphoma
Tucidinostat - Diffuse Large B-cell Lymphoma
Phase 2CompletedOu Bai, MD/PHD302017-06-012026-03-24
High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant
Busulfan, Cyclophosphamide, Fludarabine Phosphate - Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2CompletedCity of Hope Medical Center382017-05-302024-01-09
A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Rituximab (RTX), Tafasitamab, Bendamustine (BEN) - Diffuse Large B-cell Lymphoma
Phase 2 / Phase 3CompletedIncyte Corporation4532016-11-282025-07-17
Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHL
Debio 1562, Rituximab - Diffuse Large B-Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma
Phase 2CompletedDebiopharm International SA1002016-06-052024-06-12
RHCACD20MA (HS006) Combined With CHOP (Hi-CHOP) in Patients With Previously Untreated Diffuse Large B-cell Lymphoma
HS006+CHOP, Rituximab+CHOP - Diffuse Large B-cell Lymphoma
Phase 2CompletedZhejiang Hisun Pharmaceutical Co. Ltd.1372016-05-122018-04-02
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Ibrutinib, Rituximab, Gemcitabine - Diffuse Large B-Cell Lymphoma
Phase 2CompletedGrupo Español de Linfomas y Transplante Autólogo de Médula Ósea642016-04-072024-10-10
Open Label Study to Evaluate the Safety and Efficacy of Lenalidomide With MOR00208 in Patients With R-R DLBCL
Tafasitamab, Lenalidomide - Diffuse Large B-cell Lymphoma
Phase 2CompletedMorphoSys AG812016-03-292023-10-23
Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
R-CHOP - Diffuse Large B-cell Lymphoma, HIV
Phase 2CompletedUNC Lineberger Comprehensive Cancer Center392016-03-012022-10-28
An Evaluation AZD2014 Alone and in Combination With Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma
AZD 2014, Rituximab - Diffuse Large B-Cell Lymphoma
Phase 2CompletedUniversity of Birmingham362015-10-012020-11-05
A Multi-Center Study of Ibrutinib in Combination With MEDI4736 in Subjects With Relapsed or Refractory Lymphomas
Ibrutinib, MEDI4736 - Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Phase 1 / Phase 2CompletedPharmacyclics LLC.612015-05-012019-06-27
New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement
Methotrexate, Rituximab, Cytarabine - Diffuse Large B-cell Lymphoma
Phase 2CompletedInternational Extranodal Lymphoma Study Group (IELSG)792014-12-012025-07-08
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Clofarabine, Mitoxantrone - Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia
Phase 1 / Phase 2CompletedNew York Medical College412013-03-012022-10-25
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
Rituximab, CMC544, Gemcitabine and Oxaliplatine - Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedThe Lymphoma Academic Research Organisation112012-12-012016-05-23
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Bendamustine, Ofatumumab - Diffuse Large B-Cell Lymphoma
Phase 2CompletedSCRI Development Innovations, LLC222012-10-012017-11-22
A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
Obinutuzumab, Pinatuzumab Vedotin, Polatuzumab Vedotin - Follicular Lymphoma, Diffuse Large B-Cell Lymphoma
Phase 1 / Phase 2CompletedGenentech, Inc.2312012-09-272020-02-21
Erythropoietin for Management of Anemia Caused by Chemotherapy
Darbepoetin alfa, R-CHOP - Diffuse Large B-cell Lymphoma
Phase 2CompletedKosin University Gospel Hospital532012-09-012020-02-20

Showing 20 of 53. Sign in to see all of them.

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (53)  ·  Lymphoma (10)  ·  Lymphoma, Mantle-Cell (8)  ·  Lymphoma, Non-Hodgkin (6)  ·  Lymphoma, Follicular (5)  ·  Recurrence (4)  ·  Burkitt Lymphoma (3)  ·  Hodgkin Disease (3)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (3)  ·  Lymphoma, B-Cell, Marginal Zone (3)  ·  Multiple Myeloma (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (2)  ·  Leukemia, Myeloid, Acute (2)  ·  Lymphoma, B-Cell (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)

Broader conditions

Hemic and Lymphatic Diseases (53)  ·  Immune System Diseases (53)  ·  Neoplasms (53)  ·  Neoplasms by Histologic Type (53)  ·  Immunoproliferative Disorders (52)  ·  Lymphatic Diseases (52)  ·  Lymphoproliferative Disorders (52)  ·  Lymphoma, B-Cell (51)  ·  Lymphoma, Non-Hodgkin (47)  ·  Lymphoma (43)  ·  Disease Attributes (7)  ·  Pathologic Processes (7)  ·  Pathological Conditions, Signs and Symptoms (7)  ·  Hematologic Diseases (5)  ·  Leukemia (4)

Interventions

Rituximab (26)  ·  Cyclophosphamide (8)  ·  Vincristine (8)  ·  Doxorubicin (5)  ·  Etoposide (5)  ·  Prednisone (5)  ·  Bendamustine Hydrochloride (4)  ·  Gemcitabine (4)  ·  Lenalidomide (4)  ·  Oxaliplatin (4)  ·  Ifosfamide (3)  ·  Mitoxantrone (3)  ·  Carmustine (2)  ·  Clofarabine (2)  ·  Cytarabine (2)

Sponsors

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea (4)  ·  Millennium Pharmaceuticals, Inc. (3)  ·  BeiGene (2)  ·  Celgene (2)  ·  Lymphoma Study Association (2)  ·  Massachusetts General Hospital (2)  ·  National Cancer Institute (NCI) (2)  ·  Sanofi (2)  ·  UNC Lineberger Comprehensive Cancer Center (2)  ·  Acrotech Biopharma Inc. (1)  ·  Amgen Research (Munich) GmbH (1)  ·  Arbeitsgemeinschaft medikamentoese Tumortherapie (1)  ·  AstraZeneca (1)  ·  City of Hope Medical Center (1)  ·  Debiopharm International SA (1)

Countries

United States (24)  ·  Italy (12)  ·  Spain (12)  ·  France (11)  ·  United Kingdom (10)  ·  Czechia (7)  ·  Belgium (6)  ·  Poland (6)  ·  Germany (5)  ·  Austria (4)  ·  Hungary (4)  ·  Israel (4)  ·  Canada (3)  ·  China (3)  ·  Sweden (3)

Top investigators

Carlos Grande, MD (2)  ·  Luis Palomera, MD (2)  ·  Adrian Kilcoyne, MD (1)  ·  Alejandro Martin (1)  ·  Alessandro Levis, MD (1)  ·  Antonio Alcala, MD (1)

Results publications

PMID 38775302, PMID 17242396, PMID 21482186, PMID 21495023, PMID 22882209, PMID 23144193, PMID 23247661, PMID 23834234, PMID 23955074, PMID 24625556, PMID 25361987, PMID 26232170, PMID 26373676, PMID 26755709, PMID 27209293, PMID 27282998, PMID 28219694, PMID 28381416, PMID 29748443, PMID 29903707, PMID 30082475, PMID 30935953, PMID 31073022, PMID 32079690, PMID 32511983, PMID 32705923, PMID 32770353, PMID 33513372, PMID 34022150, PMID 34156440, PMID 34196165, PMID 34433649, PMID 34779360, PMID 35674661, PMID 35861632, PMID 37485564, PMID 37646664, PMID 39319495, PMID 40641817, PMID 42832423

NIH funding

2014 (2), 2004 (1), 2008 (1), 2015 (1), K01TW009488 (1), P01CA078902 (1), P30CA015704 (1), R21CA180815 (1)